BAVEBEGENE TOVACIVEC
UNII 47R2ZYV242

Substance Identification & Data

This profile provides standardized clinical and technical data for Bavebegene Tovacivec, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 47R2ZYV242.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2857059-65-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
47R2ZYV242
CAS Registry Number
2857059-65-3
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
BAVEBEGENE TOVACIVEC
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C211731
National Cancer Institute reference terminology for clinical and research data.
INN ID
12932
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
structurallyDiverse
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Bavebegene Tovacivec. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

BAVEBEGENE TOVACIVEC
BAVEBEGENE TOVACIVEC [INN]
DNA (RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA-DERIVED VACCINE VECTOR MVA-HBV ENDOGENOUS F11 PROMOTER PLUS HEPATITIS B VIRUS C-TERMINAL FRAGMENT OF PRE-S1 PROTEIN FUSED WITH PRE-S2 PROTEIN FUSED WITH NON-FUNCTIONAL POLYMERASE FUSED WITH PRE-C PROTEIN FUSED WITH CORE ANTIGEN PLUS VACCINIA VIRUS EARLY TERMINATION SIGNAL PLUS MODIFIED H5 PROMOTER PLUS HEPATITIS B VIRUS N-TERMINAL FRAGMENT OF PRE-S1 PROTEIN FUSED WITH SURFACE ANTIGEN TRANSGENE REVERSE-COMPLEMENTARY)
RECOMBINANT NON-REPLICATING VACCINIA VIRUS (MODIFIED VACCINIA ANKARA STRAIN (MVA)) ENCODING TWO CODON-OPTIMISED FUSION PROTEINS ADJACENT TO ONE ANOTHER CONTAINING HEPATITIS B VIRUS (HBV) ANTIGENS, WITH THE FIRST ONE COMPRISING THE C-TERMINAL REGION OF THE HBV PRE-S1 PROTEIN, PRE-S2, A NON-FUNCTIONAL POLYMERASE, THE PRECORE ANTIGEN, AND THE CORE ANTIGEN, PRECEDED BY A SHARK INVARIANT (SII) CHAIN SEQUENCE AND UNDER CONTROL OF THE ENDOGENOUS MVA F11 PROMOTER AND THE VACCINIA VIRUS EARLY TERMINATION SIGNAL. THE SECOND FUSION PROTEIN COMPRISES THE SIGNAL PEPTIDE FROM TISSUE PLASMINOGEN ACTIVATOR (TPA), THE N-TERMINAL FRAGMENT OF THE HBVPRE-S1 PROTEIN, AND THE HBV SURFACE ANTIGEN (HBSAG) UNDER CONTROL OF A MODIFIED H5 PROMOTER

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus